ESPR 2.06 Esperion Therapeutics, Inc.
| Range: | 0.71-3.4 | Vol Avg: | 4015189 | Last Div: | 0 | Changes: | 0.08 |
| Beta: | 1 | Cap: | 0.39B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jun 26 2013 | Empoloyees: | 240 | ||
| CUSIP: | 29664W105 | CIK: | 0001434868 | ISIN: | US29664W1053 | Country: | US |
| CEO: | Mr. Sheldon L. Koenig | Website: | https://www.esperion.com | ||||
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Stock Details
Neutral -0.10
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announc...
globenewswire.com·Wed Sep 25 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow